Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04263935

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lymphoma Gene Abnormality Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Sex eligibility

All sexes

Study type

Observational

Primary location

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

Zhengzhou, Henan, China

Location status: Recruiting

Location contact

Yanyan Liu, M.D. Ph.D

CONTACT

[email protected]

+8613838176375

Yanyan Liu, M.D. Ph.D

PRINCIPAL_INVESTIGATOR

About this study

This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed as lymphoma (according to WHO 2017 classification criteria)
  • Life expectancy no less than 3 months
  • Agreeing to sign the written informed consents

Exclusion criteria

  • Other malignant tumor history or active malignant tumor need be treated
  • Researchers determine unsuited to participate in this trial

Treatment and study plan

Primary outcomes

  1. Incidence of driver gene abnormalities

    Time frame: from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months

    the incidence of driver gene abnormalities by fixed gene testing technology

Secondary outcomes

  1. objective response rate

    Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months

    the total proportion of patients with complete response (CR) and partial response (PR)

  2. 5-year overall survival

    Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years

    from the date of first patient was included to the date of death by any cause

  3. Clinicopathological Characteristics

    Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months

    study data on clinicopathological characteristics related to incidence of driver gene abnormalities

Study contacts

Contact information is provided by the study sponsor or research team.

Yanyan Liu, M.D. Ph.D

CONTACT

[email protected]

+8613818176375

Sponsors and collaborators

Lead sponsor

Henan Cancer Hospital

Other Gov

Registry information

Important dates

Study start
2019
Primary completion
2025
Study completion
2025
First posted
Feb 11, 2020
Registry last updated
Apr 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.